poisar

Stocks · News reference

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136

Benzinga Newsdesk

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.

Read original sourceMore stocks news

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BNTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Prosper Junior Bakiny

    BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

    BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

    Read original at the-motley-fool
    BNTXMRNAMRKBMYCELGR
  2. Delveinsight

    Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

    DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

    Read original at globenewswire-inc
    PFEGMABKPTIIOVABNTX
  3. Prosper Junior Bakiny

    Is BioNTech Stock a No-Brainer Buy on the Dip?

    BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.

    Read original at the-motley-fool
    BNTXMRNAMRKPFEBMY